Author Login

Authors: Giovanna Crespi,¹ Federica Moretti,²Emanuela Giampieri,³Giovanni Luca Galimberti,¹Enrico Zanalda⁴ 

1. Dipartimento Salute Mentale e Dipendenze SERT - Monza, ASST Brianza (MB), Italy.
2. Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy.
3. Doctor specialising in psychiatry and health statistics, Monza (MB) Iyaly.
4. DISM ASL TO3 &AOU San Luigi Gonzaga, Collegno (TO), Italy.

Abstract:

The authors report a real-world experience on the treatment of cocaine use disorders (craving) in outpatient treatment subjects at the addiction centre in Monza (MB, Italy). 38 patients with Substance Use Disorder (Cocaine) were enrolled over one year for substance craving treatment with Passiflora Incarnata L Herba at a dose of 600 mg/day for a period of two months. All patients were assessed with two craving measurement scales and two clinical scales: one measuring anxiety and one depression. The assessments were carried out before treatment (To), after the first month (T1) and after the second month (T2) of Passiflora treatment. 16 patients finished the first month of treatment and only 9 completed the two months. This high attrition in the patient sample is usual in outpatient addiction treatment centres. There were no significant age differences between patients discontinuing treatment and those completing the two months of treatment. The scales administered show that patients completing two months of treatment have a significant reduction in both cocaine craving and anxiety and depression. In particular, it is reported that the most significant improvement is seen in anxiety and the dimension of craving related to it. Further and larger studies are needed to confirm the efficacy of Passiflora Incarnata L Herba in reducing cocaine craving at least for those DUS patients who have the constancy to take it regularly for at least two months.

Citation:

Giovanna Crespi . Use Of Passiflora Incarnata L. Herba In The Treatment Of Cocaine Use Disorders: The Experience Of An Addiction Center In Monza, Italy. Journal of Psychiatry Research 2024.